Table 1 Demographic and clinical data of the participants included in the study

Age at analysis, years

63 (5.8, 53–74)

61 (6.4, 52–76)

68 (8.3, 57–84)

73 (6, 54–84)

69 (7, 54–85)

% APOE ε4 allele carriers

18

33

56

62

59

% female

69

53

44

61

64

CSF Aβ_42:40 ratio

0.11 (0.01, 0.07–0.12)

0.09 (0.02, 0.04–0.12)

0.04 (0.01, 0.02–0.06)

0.04 (0.01, 0.03–0.06)

0.04 (0.01, 0.03–0.06)

CSF p-tau pg/mL

38 (10, 21–58)

30 (12, 14–56)

119 (80, 67–326)

115 (51, 57–340)

136 (59, 47–384)

CSF t-tau pg/mL

264 (65, 138–438)

204 (79, 85–416)

683 (355, 404–1568)

700 (285, 378–1890)

819 (342, 405–2000)

Education, years

25 (5, 6–20)

15 (3, 8–20)

15 (5, 8–20)

11 (5, 1–20)

11 (4, 3–20)

Global deterioration scale

1 (0.2, 1–2)

1.2 (0.5, 1–3)

1 (0, 1–1)

3 (0, 3–3)

4.2 (0.5, 4–6)

MMSE score

29 (0.9, 26–30)

29 (1, 27–30)

28.4 (1.3, 27–30)

26 (2.2, 19–30)

20.5 (4.7, 9–30)

FCSRT

44.5 (2.9, 35–48)

45.2 (3.6, 32–48)

40.6 (5.9, 33–48)

20.7 (10.8, 0–43)

12 (11, 0–43)

Semantic fluency

20.4 (5.8, 7–33)

18.1 (4.7, 12–27)

21.4 (4.9, 12–33)

9.4 (4.0, 3–16)

12.5 (4.7, 1–22)

Phonemic fluency (executive functioning)

15.8 (4.1, 9–23)

14.6 (6.6, 6–29)

16.0 (4.9, 0–26)

7.5 (4.1, 2–15)

10.5 (4.8, 2–25)

ROCF (visuospatial)

31.6 (2.8, 26–36)

29.2 (5.6, 19–36)

16.3 (4.5, 6–26)

17.6 (13.5, 2–34)

27.6 (6.0, 13–34)